# Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Study · id `cardio:ct-nct06528262` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06528262](<https://clinicaltrials.gov/study/NCT06528262>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06528262

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.

## Technical summary

Registry record NCT06528262. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-03 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 390 participants (planned count; ClinicalTrials.gov record NCT06528262, source copy `cardio:ctgov-nct06528262-2026-05-12`, retrieved 2026-10-26)
- Started: 2025-04-03 (actual) (ClinicalTrials.gov record NCT06528262, source copy `cardio:ctgov-nct06528262-2026-05-12`, retrieved 2026-10-26)
- Primary completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT06528262, source copy `cardio:ctgov-nct06528262-2026-05-12`, retrieved 2026-10-26)
- Completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT06528262, source copy `cardio:ctgov-nct06528262-2026-05-12`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06528262, source copy `cardio:ctgov-nct06528262-2026-05-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06528262-2026-05-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
- Acronym: ENAVO-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Enavogliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 0211b73375eb3a5c1baa821db36fc7f9c7825656cfeed8537a535a5b6f2ece65
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
